STAT’s biotech roundup reports that GSK has picked up regulatory approval for a therapy targeting hepatitis B. The article’s headline presents the approval as a confirmed development. The publicly available excerpt, however, does not include the drug’s proprietary name, trial data, or the regulatory agency and label details; those specifics were not reported in the accessible portion of the story.
The STAT team presented this item within a broader morning briefing of biotech headlines. Investigators, regulatory filings, or sponsor statements that would normally supply efficacy metrics, safety profiles, or indication wording are not visible in the portion of the article made public. Readers seeking the underlying evidence — randomized controlled trial design, primary and secondary endpoints, statistical outcomes, or postmarketing requirements attached to the approval — will need to consult the full STAT+ piece or the formal regulatory documentation cited by the sponsor.
Roivant and its subsidiary Priovant announced positive results from two Phase 3 studies of Lisraya in non-infectious uveitis, the STAT snapshot reports. The company already has an approval for Lisraya in dermatomyositis, and the sponsor told STAT it will pursue an expanded FDA approval for the eye indication in the first half of 2027.
The public summary notes the Phase 3 outcome as “positive” but does not reproduce numerical efficacy results, safety-event rates, endpoint definitions, or statistical analyses. The source did link to Roivant’s press release for more detail; the STAT excerpt itself did not enumerate sample sizes, dosing regimens, or the primary endpoint used to declare the trials successful. The study team’s observed outcomes, as presented in the accessible text, therefore remain high-level. For clinicians and regulators, those granular data points will matter when assessing how Lisraya compares to existing immunomodulatory options for uveitis and how the planned label expansion might be framed.
The article reports that Mark Cuban’s Cost Plus Drugs — an online pharmacy originally focused on generics and lower-cost supply chains — is expanding into experimental rare-disease therapies. STAT frames this as a strategic shift from a business model centered on low-cost generics toward involvement in more complex, investigational medicines.
STAT’s public excerpt characterizes the move but does not name specific rare-disease candidates, development partners, or commercialization strategies. The report notes that the company has been “mostly selling generic drugs,” and that it is now getting into “a much more complicated field — experimental rare disease therapies.” The STAT piece is gated as a STAT+ exclusive, and the paywall prevents the excerpt from supplying further detail on licensing, manufacturing, regulatory interactions, or clinical-stage programs that Cost Plus may be targeting.
The accessible portion of the STAT article is a compact biotech briefing that aggregates several corporate and clinical headlines: a GSK hepatitis B approval, Roivant’s Phase 3 successes with Lisraya, and Cost Plus Drugs’ strategic expansion. The piece also references other items in STAT’s biotech feed, including an Immatics cancer program update, but those references in the public excerpt are limited to headlines.
The publicly available text did not report trial methodology (randomization, blinding), primary and secondary endpoint definitions, effect sizes, p-values, safety-event frequencies, dosing schedules, patient demographics, or regulatory documents. The STAT brief links to company announcements for some items; it did not itself reproduce the detailed clinical evidence or regulatory filings. The article therefore functions as a curated news summary rather than a source of primary clinical data.
Limitations and next steps
This rewrite relies only on the information present in the STAT excerpt. To evaluate clinical impact or to inform practice, clinicians should consult the full STAT+ article, the sponsors’ detailed releases, peer-reviewed trial reports, or the regulatory agency’s approval package. The public excerpt leaves unanswered questions about trial design, comparative performance against existing therapies, safety signals, and the exact regulatory language of the GSK hepatitis B approval — all items that would be necessary for clinical assessment and were not included in the accessible portion of the source.